Company: FTII
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001641172-25-025250
Chunk: 38

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 38
---
 Account funds while maintaining compliance with the trust agreement. Formation and operational
costs are reviewed and monitored by the CODM to manage and forecast cash to ensure enough capital is available to complete a business
combination within the business combination period. The CODM also reviews formation and operational costs to manage, maintain and enforce
all contractual agreements to ensure costs are aligned with all agreements and budget.

 Schedule
of Segment Reporting

    June 30, 2025  
    December 31,  2024 
  
    Cash 
    $160,723  
    $56,768 
  
    Investments held in Trust Account 
    $9,133,890  
    $26,447,350 

    For the Six Months Ended June 30, 2025  
    For the  Three Months Ended June 30, 2025 
  
    Formation and operating costs 
    $532,572  
    $108,736 

    Interest income earned on investments held in Trust Account 
    $272,304  
    $72,477 

All
other segment items included in net loss are reported on the condensed statements of operations and described within their respective
disclosures.

Note
10 – Subsequent Events

The
Company evaluated subsequent events and transactions that occurred after the balance sheet date. Based upon this review the Company did
not identify any subsequent events, other than those noted below, that would have required adjustment or disclosure in the unaudited
condensed financial statements.

Amended
Merger Agreement

On
August 12, 2025, FutureTech II Acquisition Corp., a Delaware corporation (the “Company”), entered into an Amended and Restated
Agreement and Plan of Merger (the “Merger Agreement”), by and among the Company, Longevity Biomedical, Inc., a Delaware corporation
(“Longevity”), LBI Merger Sub, Inc., a Delaware corporation and direct, wholly-owned subsidiary of the Company (“Merger
Sub”), and Andrew Leo, solely in the capacity as seller representative.

The
Merger Agreement provides that (i) Longevity will consummate Target Acquisitions (as defined below) upon the terms and subject to conditions
set forth therein and pursuant to the Target Acquisition Agreements (as defined in the Merger Agreement), and (ii) immediately following
the consummation of the Target Acquisitions, the Company will merge with and into PubCo (the “Reorganization Merger”) with